Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Research-based biotech company Enzymotec has reported positive results from its lipid-based ingredient line for infant nutrition clinical trials.
Subscribe to our email newsletter
The trials are part of business development strategy to develop and market directly or through Enzymotec’s affiliated companies a line of products resembling the lipids found in mother’s milk.
The company has completed clinical trial on InFat, which is a beta-palmitate ingredient that resembles the fat composition and properties of human milk fat.
Enzymotec has also conducted four clinical trials on new born infants.
Enzymotec Infant Nutrition R&D director Yael Lifshitz said the clinical trials plan represents Enzymotec’s exloration of the special characteristics of human milk.
"We developed this innovative ingredient and educated the premium infant formula market over the last several years,” Lifshitz added.
”Enzymotec invested 10% of its revenue in research and development-a percentage considered among the highest in the industry."